Free Trial

Pulmonx (LUNG) Stock Price, News & Analysis

+0.34 (+4.58%)
(As of 07/15/2024 ET)
Today's Range
50-Day Range
52-Week Range
388,955 shs
Average Volume
466,155 shs
Market Capitalization
$301.21 million
P/E Ratio
Dividend Yield
Price Target

Pulmonx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
102.5% Upside
$15.71 Price Target
Short Interest
3.42% of Float Sold Short
Dividend Strength
News Sentiment
1.19mentions of Pulmonx in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$94,585 Sold Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.98 out of 5 stars

Medical Sector

368th out of 913 stocks

Surgical & Medical Instruments Industry

45th out of 100 stocks

LUNG stock logo

About Pulmonx Stock (NASDAQ:LUNG)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Stock Price History

LUNG Stock News Headlines

The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
Pulmonx Surge After Strong 1Q Performance
The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
Q1 2024 Pulmonx Corp Earnings Call
Navigating 6 Analyst Ratings For Pulmonx
See More Headlines
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$68.68 million
Book Value
$3.09 per share


Free Float
Market Cap
$299.69 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

LUNG Stock Analysis - Frequently Asked Questions

How have LUNG shares performed this year?

Pulmonx's stock was trading at $12.75 at the start of the year. Since then, LUNG stock has decreased by 39.1% and is now trading at $7.76.
View the best growth stocks for 2024 here

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) announced its earnings results on Wednesday, May, 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm earned $18.85 million during the quarter, compared to analysts' expectations of $17.54 million. Pulmonx had a negative net margin of 80.46% and a negative trailing twelve-month return on equity of 48.09%.

When did Pulmonx IPO?

Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUNG) was last updated on 7/15/2024 by Staff

From Our Partners